Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7UIZ1
|
|||
| Drug Name |
BGB-A425
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | ||
| Company |
BeiGene
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis A virus cellular receptor 2 (TIM3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of BeiGene. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.